CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Australia

2019-11-29
Price :
Published : Nov-2019
No. of Pages : 180

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Australia

Summary

GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Australia”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Australia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Australia. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

Australia has one of the fastest growing pharmaceutical markets in the world, providing safe and affordable health care to its citizen. The pharmaceutical market in Australia was valued at $10.58B in 2011 and increased at CAGR of 3.3% to $11.69B in 2018. The market is expected to reach $13.33B in 2022. However, the market value in terms of Australian Dollar was AUD$10.26B in 2011 and increased at a CAGR of 6% to AUD$15.65B in 2018. It is expected to reach AUD$19.78B in 2022. The difference is due to currency exchange fluctuations. In 2015, the medical device market in Australia was worth $8.4B, which increased to $9.5B in 2018 at a CAGR of 4.2%. It is expected to reach $11.9B in 2023. The Australian healthcare market is driven by universal healthcare coverage, wide access to government-subsidized medicine, growing elderly population and its associated disease burden, well-defined regulatory guidelines, the usage of substitute drugs and the introduction of a new manufacturing policy.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the Australia, and includes –
– An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
– Profiles and SWOT analyses of the major players in the pharmaceutical market (Sanofi, Pfizer, Astrazeneca, GSK, and Clinuvel) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Siemens, Stryker, and Zimmer Biomet)
– Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Australia
– Porter’s five forces analysis for pharmaceutical and medical devices market of Australia
– An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
– Information regarding the health-tech landscape of the country along with the major health-tech deals
– Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
– An overview of the opportunities and challenges to growth in the Australian healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to –
– Develop business strategies by understanding the trends shaping and driving the Australian healthcare market
– Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
– Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
– Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
– Identify, understand, and capitalize on the opportunities and challenges in the Australian healthcare market

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Impact on Publicly Traded Bio/Pharma Companies – Coronavirus Disease (COVID-19) 2019 Impact Report

Impact on Publicly Traded Bio/Pharma Companies - Coronavirus Disease (COVID-19) 2019 Impact Report Summary The Coronavirus (COVID-19) company impact report analyses how the pandemic has impact the top 20 Mega Cap Bio/Pharma Companies revenue, future revenue, and market capitalization. Scope - This report gives an important expert analysis on how COVID-19 has affected, and will continue to affect, the top 20 Mega Cap Bio/Pharma Companies. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis. Reasons to Buy - An overview of how the top 20 Mega Cap Bio/Pharma Companies have been affected, and will continue to be affected, by the COVID-19 pandemic.......
$695

Acute Myeloid Leukemia (AML) – Opportunity Analysis and Forecasts to 2029

Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029 Summary Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. Until recently, chemotherapy and hypomethylating agents were the only treatment options, but since 2017 this has changed with the introduction of premium-priced novel therapies. The global AML market is expected to grow from $1.4B in 2019 to $5.1B in 2029 at a compound annual growth rate (CAGR) of 13.6%. This dramatic growth is driven by the launch of 16 new pipeline agents in the 7MM and 12 in China, by the......
$10995

Acute Myeloid Leukemia – Epidemiology Forecast to 2029

Acute Myeloid Leukemia - Epidemiology Forecast to 2029 Summary Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow in which the bone marrow produces abnormal red blood cells, white blood cells, or platelets, and generally progresses at a rapid pace. AML is more common in the elderly, is associated with severe complications and high mortality, and accounts for a disproportionately high number of cancer-related deaths. AML is often called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, and acute nonlymphocytic leukemia. In 2019, there were 72,164 diagnosed incident cases of AML in the 8MM in men and women combined for ages 18 years and older. GlobalData epidemiologists estimate that globally, cases will rise to 90,264 at an Annual Gr......
$3995

Aseptic Sampling Market by Type (Manual [Type (Traditional, Single-use), Product (Bags, Bottles, Syringes, Accessories)], Automatic), Application (Upstream, Downstream), Technique (Off-line, On-line), End User (R&D, CMO, CRO) – Global Forecast to 2025

 “The aseptic sampling market is projected to grow at a CAGR of 12.4% during the forecast period (2020–2025).” The global aseptic sampling market size is projected to reach USD 474 million by 2025 from USD 264 million in 2020, at a CAGR of 12.4%. The growth of this market is driven majorly by factors such as the increasing demand for biopharmaceuticals, stringent government regulations to ensure drug safety, and funding to support life sciences research activities. On the other hand, issues related to leachables and extractable from single-use products are restraining market growth. “By type, the manual aseptic sampling segment is expected to grow at the highest CAGR during the forecast period.” Based on type, the aseptic sampling market is segmented into manual aseptic......
$4950

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity

Impact of COVID-19 on Pharmaceutical Social Media Influencer Activity Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussing online about the virus. Scope The report includes 10 Influencers - - Eight therapy areas: Cardiovascular, Metabolic Disord......
$995

Digital Biomarkers – Coronavirus Disease 2019 (COVID-19) Case Study

Digital Biomarkers - Coronavirus Disease 2019 (COVID-19) Case Study Summary The ongoing COVID-19 crisis has seen social distancing and lockdown measures implemented around the world, which has had widespread effects on the healthcare industry, particularly in the ways that patients and healthcare professionals can safely interact while minimizing risks of viral transmission. Remote patient monitoring and the collection of digital biomarkers by connected devices has emerged as an important approach to support patients and healthcare systems during the pandemic. This case study assesses how connected devices and digital biomarkers can be used during the COVID-19 pandemic and beyond. Key Highlights - Digital biomarkers are an important addition to the armamentarium of tools supporting pa......
$595

Animal Parasiticides Market by Product (Ectoparasiticides, Endectocide (Ear Tags, Tablets, Dips, Injectables, Spot-on, Collars) Animal (Dogs, Cats, Cattle, Sheep, Goats, Horses) End-user (Veterinary Hospitals) – Global Forecast to 2025

“The animal parasiticides market is projected to grow at a CAGR of 7.2% between 2020 and 2025.” The animal parasiticides market is expected to reach USD 13.7 billion by 2025 from USD 9.7 billion in 2020, at a CAGR of 7.2% from 2020 to 2025. Increasing pet expenditure and the growing incidences of parasitic infections are some major factors driving the market. However, accounting for the diversity of parasitic species while developing effective medications and parasiticides is one of the major challenges for players operating in this market. “Ecto parasiticides segment to witness the highest growth rate during the forecast period.” In the market, by type, ecto parasiticides are expected to register the highest CAGR during the forecast period. The high growth of this segment......
$4950

Health Insurance Implications – Coronavirus Disease (COVID-19) Sector Impact – June 2020

Health Insurance Implications - Coronavirus Disease (COVID-19) Sector Impact - June 2020 Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. The virus is also having a growing impact on the global economy including the health insurance industry. This report reflects how government bodies and healthcare authorities are reacting to protect policyholder interest and minimize the impact on the health insurance industry during the COVID-19 crisis. Key Highlights - A number of reports estimated the impact of COVID-19 on unemployment rates and loss of E......
$495

Laboratory Information Management System (LIMS) Market by Type (Broad, Industry-specific), Component (Software, Services), Delivery (On premise, Remote, Cloud), End User (CRO, Pharma, Biotech, Chemical, Agriculture, FnB, Oil, Gas) – Global Forecast to 2025

“The global laboratory information management systems market is projected to grow at a CAGR of 12.1% during the forecast period (2020–2025)” The global LIMS market is estimated to reach USD 1.7 billion by 2025 from USD 1.0 billion in 2020, at a CAGR of 12.1%. The increasing adoption of LIMS to comply with stringent regulatory requirements, technological advancements in LIMS offerings, increasing R&D expenditure in pharmaceutical and biotechnology companies, and the growing adoption of cloud-based LIMS are some of the factors driving the growth of this market. However,the high maintenance and service costs and the lack of integration standards for LIMS are expected to restrain the growth of this market. “Services segment to grow at the highest CAGR during the forecast peri......
$4950

Non-Alcoholic Steatohepatitis – Epidemiology Forecast to 2029

Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2029 Summary Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage (NIDDK, 2016). Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem (NIDDK, 2016). GlobalData epidemiologists utilized primary research and comprehensive, country-specific data from peer-reviewed journal articles when available, to arrive at a meaningful, in-depth analysis and forecast for the total and diagnosed prevalent cases of NASH. For all the 7MM, NASH cas......
$3995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy